JP2013541333A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013541333A5 JP2013541333A5 JP2013529096A JP2013529096A JP2013541333A5 JP 2013541333 A5 JP2013541333 A5 JP 2013541333A5 JP 2013529096 A JP2013529096 A JP 2013529096A JP 2013529096 A JP2013529096 A JP 2013529096A JP 2013541333 A5 JP2013541333 A5 JP 2013541333A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- bacteriophage
- protein
- fragment
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241001515965 unidentified phage Species 0.000 claims 35
- 108090000623 proteins and genes Proteins 0.000 claims 30
- 102000004169 proteins and genes Human genes 0.000 claims 30
- 239000012634 fragment Substances 0.000 claims 20
- 241000894006 Bacteria Species 0.000 claims 11
- 241000588626 Acinetobacter baumannii Species 0.000 claims 10
- 241000588724 Escherichia coli Species 0.000 claims 10
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 241000588747 Klebsiella pneumoniae Species 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 230000000844 anti-bacterial effect Effects 0.000 claims 9
- 230000000845 anti-microbial effect Effects 0.000 claims 9
- 150000007523 nucleic acids Chemical group 0.000 claims 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 8
- 241000191967 Staphylococcus aureus Species 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 208000015181 infectious disease Diseases 0.000 claims 5
- 208000035143 Bacterial infection Diseases 0.000 claims 4
- 208000022362 bacterial infectious disease Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000000069 prophylactic effect Effects 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 101000870242 Bacillus phage Nf Tail knob protein gp9 Proteins 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 230000009089 cytolysis Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 210000004400 mucous membrane Anatomy 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 206010011409 Cross infection Diseases 0.000 claims 1
- 208000008960 Diabetic foot Diseases 0.000 claims 1
- 206010023424 Kidney infection Diseases 0.000 claims 1
- 241000588748 Klebsiella Species 0.000 claims 1
- 208000032376 Lung infection Diseases 0.000 claims 1
- 206010029803 Nosocomial infection Diseases 0.000 claims 1
- 206010037596 Pyelonephritis Diseases 0.000 claims 1
- 108010039491 Ricin Proteins 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 238000001574 biopsy Methods 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000003638 chemical reducing agent Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 231100000676 disease causative agent Toxicity 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 206010040872 skin infection Diseases 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38401510P | 2010-09-17 | 2010-09-17 | |
| US61/384,015 | 2010-09-17 | ||
| PCT/PT2011/000031 WO2012036580A2 (en) | 2010-09-17 | 2011-09-19 | Antibacterial phage, phage peptides and methods of use thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015243657A Division JP6234983B2 (ja) | 2010-09-17 | 2015-12-14 | 抗菌性ファージ、ファージペプチド、及びそれらの使用方法 |
| JP2016181177A Division JP6355691B2 (ja) | 2010-09-17 | 2016-09-16 | 抗菌性ファージ、ファージペプチド、及びそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013541333A JP2013541333A (ja) | 2013-11-14 |
| JP2013541333A5 true JP2013541333A5 (cg-RX-API-DMAC7.html) | 2015-04-16 |
| JP6058540B2 JP6058540B2 (ja) | 2017-01-11 |
Family
ID=45755483
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013529096A Active JP6058540B2 (ja) | 2010-09-17 | 2011-09-19 | 抗菌性ファージ、ファージペプチド、及びそれらの使用方法 |
| JP2015243657A Active JP6234983B2 (ja) | 2010-09-17 | 2015-12-14 | 抗菌性ファージ、ファージペプチド、及びそれらの使用方法 |
| JP2016181177A Active JP6355691B2 (ja) | 2010-09-17 | 2016-09-16 | 抗菌性ファージ、ファージペプチド、及びそれらの使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015243657A Active JP6234983B2 (ja) | 2010-09-17 | 2015-12-14 | 抗菌性ファージ、ファージペプチド、及びそれらの使用方法 |
| JP2016181177A Active JP6355691B2 (ja) | 2010-09-17 | 2016-09-16 | 抗菌性ファージ、ファージペプチド、及びそれらの使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9222077B2 (cg-RX-API-DMAC7.html) |
| EP (4) | EP3443970B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6058540B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN103732235B (cg-RX-API-DMAC7.html) |
| AU (3) | AU2011302722B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013006400B1 (cg-RX-API-DMAC7.html) |
| CA (3) | CA3048783C (cg-RX-API-DMAC7.html) |
| ES (3) | ES2956367T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3789031T3 (cg-RX-API-DMAC7.html) |
| PT (2) | PT2616087T (cg-RX-API-DMAC7.html) |
| RU (2) | RU2725726C2 (cg-RX-API-DMAC7.html) |
| SG (1) | SG188566A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012036580A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3048783C (en) * | 2010-09-17 | 2022-05-24 | Tecnifar-Industria Tecnica Farmaceutica, S.A. | Antibacterial phage, phage peptides and methods of use thereof |
| CA2867418C (en) * | 2012-03-19 | 2020-03-10 | Tecnifar-Industria Tecnica Farmaceutica, S.A. | Compositions comprising cocktails of antibacterial phages and uses thereof for the treatment of bacterial infections |
| NZ701651A (en) * | 2012-05-07 | 2016-09-30 | Micreos B V | A bacteriophage for biocontrol of salmonella and in the manufacturing or processing of foods |
| EP2799063A1 (en) | 2013-04-30 | 2014-11-05 | Ferring B.V. | Bacteriophage therapy |
| EP2865383A1 (en) * | 2013-10-25 | 2015-04-29 | Pherecydes Pharma | Phage therapy of pseudomonas infections |
| EP2893933A1 (en) * | 2014-01-10 | 2015-07-15 | Pherecydes Pharma | Phage Therapy of E coli infections |
| CN103981154B (zh) * | 2014-05-28 | 2016-07-06 | 大连理工大学 | 一种铜绿假单胞菌噬菌体及其在水貂出血性肺炎预防中的应用 |
| GB2543453A (en) | 2014-06-26 | 2017-04-19 | Univ Rockefeller | Acinetobacter lysins |
| EP3018201A1 (en) * | 2014-11-07 | 2016-05-11 | Pherecydes Pharma | Phage therapy |
| US10221398B2 (en) * | 2014-12-16 | 2019-03-05 | C3J Therapeutics, Inc. | Compositions of and methods for in vitro viral genome engineering |
| US10744189B2 (en) * | 2015-09-17 | 2020-08-18 | Contrafect Corporation | Lysin polypeptides active against Gram-negative bacteria |
| US10287560B2 (en) * | 2016-03-28 | 2019-05-14 | Illumina, Inc. | Recombinase mutants |
| AU2017371484B2 (en) * | 2016-12-05 | 2022-09-15 | Technophage, Investigação e Desenvolvimento Em Biotecnologia SA | Bacteriophage compositions comprising respiratory antibacterial phages and methods of use thereof |
| EP3584315A4 (en) * | 2017-02-17 | 2020-09-16 | Intron Biotechnology, Inc. | NEW BACTERIOPHAGE PSE-AEP-4 OF PSEUDOMONAS AERUGINOSA AND ITS USE IN INHIBITION OF THE PROLIFERATION OF PSEUDOMONAS AERUGINOSA |
| GB201712145D0 (en) * | 2017-07-28 | 2017-09-13 | Univ Leuven Kath | Novel dnase |
| US11958890B2 (en) | 2018-05-30 | 2024-04-16 | Lysando Ag | Antimicrobial proteins |
| WO2020130652A2 (ko) * | 2018-12-18 | 2020-06-25 | 연세대학교 산학협력단 | 세균을 용균하는 신규한 박테리오파지 |
| US20220073567A1 (en) * | 2018-12-24 | 2022-03-10 | Mikroliz Biyoteknoloji San. Ve Tic. Ltd. Sti. | Acinetobacter baumannii bacteriophage mikab48 or lytic protein derived from the bacteriophage |
| US12396460B2 (en) * | 2019-06-17 | 2025-08-26 | Precisio Biotix Therapeutics, Inc. | Bacterial control through dispersion of bacteriophage powders |
| RU2717420C1 (ru) * | 2019-06-28 | 2020-03-23 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 327 (500321), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
| RU2717435C1 (ru) * | 2019-06-28 | 2020-03-23 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 326 (500320), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
| RU2717022C1 (ru) * | 2019-06-28 | 2020-03-17 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 328 (500322), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
| RU2717451C1 (ru) * | 2019-06-28 | 2020-03-23 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 323 (500317), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
| RU2717972C1 (ru) * | 2019-06-28 | 2020-03-27 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 324 (500318), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
| RU2717973C1 (ru) * | 2019-06-28 | 2020-03-27 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 322 (500316), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
| RU2717026C1 (ru) * | 2019-06-28 | 2020-03-17 | Акционерное общество "Научно-производственное объединение по медицинским иммунобиологическим препаратам "Микроген" | Штамм бактериофага Pseudomonas aeruginosa N 325 (500319), предназначенный для приготовления моно- и поливалентных лечебно-профилактических препаратов бактериофагов |
| RU2707505C1 (ru) * | 2019-09-17 | 2019-11-27 | федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО "ПИМУ" Минздрава России) | Способ лечения бактериальных инфекций дыхательных путей |
| US20210187046A1 (en) | 2019-12-19 | 2021-06-24 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Cocktail compositions comprising respiratory antibacterial phages and methods of use thereof |
| CN113214364B (zh) * | 2020-01-21 | 2022-11-22 | 天津大学 | 一种多重耐药鲍曼不动杆菌识别元件的挖掘与验证 |
| FR3110574A1 (fr) * | 2020-05-20 | 2021-11-26 | Vetophage | Capture de bacteries a l’aide de bacteriophages ou de proteines de bacteriophage |
| CN115397994B (zh) | 2020-05-22 | 2023-03-28 | 株式会社莱森科技 | 新型多肽、融合多肽和包含其的抗革兰氏阴性菌的抗生素 |
| WO2022040592A1 (en) * | 2020-08-20 | 2022-02-24 | The Board Of Regents Of The University Of Texas System | Combination immunotherapy methods for the treatment of cancer |
| US20240415904A1 (en) * | 2021-05-12 | 2024-12-19 | Biomx Ltd. | Staphylococcus bacteriophage and uses thereof |
| WO2023101639A1 (en) * | 2021-11-30 | 2023-06-08 | Yildiz Teknik Universitesi | Antimicrobial agent for lysis of s. aureus |
| CN114807106B (zh) * | 2022-04-25 | 2023-09-01 | 昆明市延安医院 | 一种裂解酶pEf51和穿孔素蛋白pEf191的应用 |
| WO2024182314A2 (en) * | 2023-02-27 | 2024-09-06 | The Regents Of The University Of California | Proteins that inhibit cyclic-oligonucleotide-based anti-phage signaling system (cbass) |
| US20250160335A1 (en) * | 2023-11-16 | 2025-05-22 | The United States Of America, As Represented By The Secretary Of Agriculture | Formulation of a lytic bacteriophage cocktail for biocontrol of shiga toxin-producing escherichia coli strains |
| CN119139561A (zh) * | 2024-11-15 | 2024-12-17 | 浙江大学 | 一种噬菌体复合水凝胶及其制备方法和在促进牙槽骨修复中的应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| DE59309972D1 (de) * | 1992-06-25 | 2000-04-20 | Aventis Res & Tech Gmbh & Co | Pseudomonas aeruginosa und seine Verwendung zur Herstellung von L-Rhamnose |
| EP0755441A4 (en) | 1994-04-05 | 2000-01-26 | Exponential Biotherapies Inc | Antibacterial therapy with genotypically modified bacteriophage |
| RU2112800C1 (ru) * | 1996-03-29 | 1998-06-10 | Государственный научный центр прикладной микробиологии | Штамм пилеспецифического бактериофага pseudomonas aeruginosa гнцпм n 03, используемый для приготовления лечебного препарата против синегнойной палочки |
| AU734420B2 (en) | 1996-04-15 | 2001-06-14 | Nymox Corporation | Compositions containing bacteriophages and methods of using bacteriophages to treat infections |
| US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
| US7138419B2 (en) * | 2000-12-27 | 2006-11-21 | Corus Pharma, Inc. | Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate |
| DE10115310A1 (de) | 2001-03-28 | 2002-10-10 | Nodar A Daniela | Bakteriophagen-Präparation |
| CN1643139A (zh) * | 2002-03-25 | 2005-07-20 | 沃里克大学 | 抗菌剂 |
| GB0300597D0 (en) * | 2003-01-10 | 2003-02-12 | Microbiological Res Authority | Phage biofilms |
| US20050095222A1 (en) | 2003-10-29 | 2005-05-05 | Taro Suzuki | Allergen inhibitor, allergen-inhibiting method, allergen-inhibiting fiber and allergen-inhibiting sheet |
| WO2006047871A1 (en) | 2004-11-02 | 2006-05-11 | Gangagen Life Sciences Inc. | Encapsulated bacteriophage formulation |
| US20090130196A1 (en) | 2004-11-02 | 2009-05-21 | Kishore Murthy | Bacteriophage composition |
| WO2006063176A2 (en) | 2004-12-06 | 2006-06-15 | The Government Of The Usa As Representedtd By The Secretary Of The Dept Of Health And Human Services | Inhibition of biofilm formation using bacteriophage |
| US20080260697A1 (en) | 2005-05-26 | 2008-10-23 | Gangagen Life Sciences Inc. | Bacterial Management in Animal Holding Systems |
| ES2536852T3 (es) * | 2006-05-05 | 2015-05-28 | Gangagen, Inc. | Actividades antimicrobianas derivadas de fagos |
| IE20060488A1 (en) * | 2006-06-29 | 2008-01-09 | Teagasc Agric Food Dev Authori | Recombinant staphylococcal phage lysin as an antibacterial agent |
| CN101003793A (zh) * | 2007-01-11 | 2007-07-25 | 中国人民解放军第三军医大学 | 噬菌体对环境中致病菌的净化技术 |
| WO2008121830A2 (en) | 2007-03-30 | 2008-10-09 | National Research Council Of Canada | Phage receptor binding proteins for antibacterial therapy and other novel uses |
| EP2103308A1 (de) * | 2008-03-20 | 2009-09-23 | PhytoLine GmbH | Verfahren zur Herstellung eines Gemisches von Bakteriophagen und deren Verwendung für die Therapie von Antibiotika-resistenten Staphylococcen |
| CA2638130A1 (en) * | 2008-07-21 | 2010-01-21 | Canadian Forest Products Ltd. | Composite wood product and method of manufacture utilizing wood infected by bark beetles |
| EP2318531A4 (en) * | 2008-07-24 | 2011-11-09 | Us Agriculture | TO RESISTANCE DEVELOPMENT REFRACTORY ANTIMICROBIAL ACTIVE SUBSTANCES |
| GB0815484D0 (en) * | 2008-08-26 | 2008-10-01 | Univ Leuven Kath | Antibacterial agents |
| US8563504B2 (en) | 2008-10-10 | 2013-10-22 | Lusomedicamenta, S.A. | Antibacterial phage peptides and methods of use thereof |
| KR101016918B1 (ko) * | 2009-01-08 | 2011-02-25 | 주식회사 인트론바이오테크놀로지 | 박테리아 특이적 넓은 항균 활성을 갖는 신규한 리신 단백질 |
| ES2963904T3 (es) | 2009-02-06 | 2024-04-03 | Technophage Investig E Desenvolvimento Em Biotecnologia Sa | Fago antibacteriano, péptidos de fago y sus métodos de uso |
| KR101701890B1 (ko) | 2009-06-26 | 2017-02-02 | 뤼산도 아게 | 항균제 |
| CA3048783C (en) * | 2010-09-17 | 2022-05-24 | Tecnifar-Industria Tecnica Farmaceutica, S.A. | Antibacterial phage, phage peptides and methods of use thereof |
| US9605250B2 (en) * | 2011-04-12 | 2017-03-28 | Gangagen, Inc. | Chimeric antibacterial polypeptides |
-
2011
- 2011-09-19 CA CA3048783A patent/CA3048783C/en active Active
- 2011-09-19 PT PT11820825T patent/PT2616087T/pt unknown
- 2011-09-19 PL PL20194660.5T patent/PL3789031T3/pl unknown
- 2011-09-19 US US13/823,519 patent/US9222077B2/en active Active
- 2011-09-19 CA CA2811472A patent/CA2811472C/en active Active
- 2011-09-19 PT PT181927666T patent/PT3443970T/pt unknown
- 2011-09-19 ES ES20194660T patent/ES2956367T3/es active Active
- 2011-09-19 WO PCT/PT2011/000031 patent/WO2012036580A2/en not_active Ceased
- 2011-09-19 EP EP18192766.6A patent/EP3443970B1/en active Active
- 2011-09-19 EP EP11820825.5A patent/EP2616087B1/en active Active
- 2011-09-19 EP EP20194660.5A patent/EP3789031B1/en active Active
- 2011-09-19 CA CA3154006A patent/CA3154006C/en active Active
- 2011-09-19 ES ES11820825T patent/ES2703629T3/es active Active
- 2011-09-19 SG SG2013019385A patent/SG188566A1/en unknown
- 2011-09-19 RU RU2017106290A patent/RU2725726C2/ru active
- 2011-09-19 RU RU2013117275A patent/RU2614114C2/ru active
- 2011-09-19 ES ES18192766T patent/ES2825050T3/es active Active
- 2011-09-19 BR BR112013006400-5A patent/BR112013006400B1/pt active IP Right Grant
- 2011-09-19 EP EP23178561.9A patent/EP4332217A3/en active Pending
- 2011-09-19 CN CN201180054190.XA patent/CN103732235B/zh active Active
- 2011-09-19 AU AU2011302722A patent/AU2011302722B2/en active Active
- 2011-09-19 JP JP2013529096A patent/JP6058540B2/ja active Active
-
2015
- 2015-11-13 AU AU2015255313A patent/AU2015255313C1/en active Active
- 2015-11-17 US US14/943,082 patent/US9399049B2/en active Active
- 2015-12-14 JP JP2015243657A patent/JP6234983B2/ja active Active
-
2016
- 2016-07-22 US US15/216,875 patent/US9737579B2/en active Active
- 2016-08-25 AU AU2016219667A patent/AU2016219667B2/en active Active
- 2016-09-16 JP JP2016181177A patent/JP6355691B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013541333A5 (cg-RX-API-DMAC7.html) | ||
| RU2013117275A (ru) | Бактериофаги, фаговые пептиды и способы их применения | |
| JP2012517225A5 (cg-RX-API-DMAC7.html) | ||
| Nguyen et al. | Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital‐acquired infections: a scientific review | |
| Weber-Dabrowska et al. | Bacteriophage therapy for infections in cancer patients | |
| Howard et al. | Acinetobacter baumannii: an emerging opportunistic pathogen | |
| Bhargava et al. | Phage therapeutics: from promises to practices and prospectives | |
| RU2011134315A (ru) | Бактериофаги, белки бактериофагов и способы их применения | |
| JP6769871B2 (ja) | Ｅ．ｃｏｌｉ感染のファージを用いての治療 | |
| BR112017009545B1 (pt) | Composição antibacteriana farmacêutica ou veterinária e método in vitro para a preparação de uma composição farmacêutica ou veterinária | |
| US20240024391A1 (en) | Phage therapy | |
| BR112016009062B1 (pt) | Composição antibacteriana, método para a preparação de uma composição, método in vitro para prever ou determinar a eficácia de uma terapia de bacteriófago em um indivíduo e método in vitro para selecionar um indivíduo ou determinar se um indivíduo é susceptível de se beneficiar de uma terapia com bacteriófagos | |
| El-Gayar et al. | Antivirulence and wound healing effects of royal jelly and garlic extract for the control of MRSA skin infections | |
| Wu et al. | Application of S-thanatin, an antimicrobial peptide derived from thanatin, in mouse model of Klebsiella pneumoniae infection | |
| Kamel et al. | Characterization of bee venom and its synergistic effect combating antibiotic resistance of Pseudomonas aeruginosa | |
| CN107177580B (zh) | 一种广谱新型嵌合裂解酶GBS-PlySb及其编码基因和应用 | |
| MORRISETTE et al. | Bacteriophage-antibiotic combinations: A promising alternative for refractory infections? | |
| Lee et al. | Enterococcus Phage vB_EfaS_HEf13 as an Anti-biofilm Agent against Enterococcus faecalis | |
| Bilska-Stokłosa et al. | Streptococcus constellatus as an aetiological factor of extensive neck phlegmon complicated by sepsis–case study | |
| Wang et al. | A novel chimeric endolysin Cly2v shows potential in treating streptococci-induced bovine mastitis and systemic infections | |
| WO2016146037A1 (zh) | 用于抑制/瓦解生物被膜的抑制剂及其应用 | |
| Orole et al. | Distribution of resistance genes and resistance profile of methicillin-resistant Staphylococcus aureus among animal handlers in Animal Market, Jos | |
| PREDA et al. | The Need to Develop New Antimicrobial Molecules, as Revealed by in vitro Assessment of Drug Resistance in Staphylococcal Skin Infections Treated with Autologous Bacterial Vaccine | |
| Su et al. | Cutaneous type of nocardiosis caused by Nocardia brasiliensis in an elderly patient | |
| Hameed | A comparative study of antibacterial activity between honey and antibiotics against some pathogenic bacteria. |